Trials Sponsors Conditions Drugs Pricing

Conditions

Advanced Cancer Weight Loss

Keywords

Advanced CancerWeight LossCachexiaOlanzapineZyprexaFluoxetineSymbyax

Outcome Measures

Primary Outcomes (1)

Maximum Tolerated Dose (MTD)
Toxicity evaluation after one 28-day cycle (& each dose level).

Study Arms (1)

Olanzapine

EXPERIMENTAL

Olanzapine 2.5 mg by mouth (PO) Daily x 28 days, increasing about every 3-14 days in increments of 2.5-5 mg until the designated dose for that cohort is reached.

Drug: Olanzapine

Interventions

OlanzapineDrug

2.5 mg by mouth (PO) Daily x 28 days, increasing about every 3-14 days in increments of 2.5-5 mg until the designated dose for that cohort is reached.

Also known as: Zyprexa, Fluoxetine, Symbyax

Olanzapine

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Sexall

Healthy VolunteersNo

Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

Patient with confirmed advanced cancer.
Patients with decreased daily caloric intake (\<1500 Calories/day), or with a weight loss equivalent to 10% of body weight over six months

Sponsors & Collaborators

M.D. Anderson Cancer Center
Otherlead

Study Sites (1)

UT MD Anderson Cancer Center

Houston, Texas, 77030, United States

MeSH Terms

Conditions

Weight LossCachexia

Interventions

OlanzapineFluoxetineolanzapine-fluoxetine combination

Condition Hierarchy (Ancestors)

Body Weight ChangesBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsThinness

Intervention Hierarchy (Ancestors)

BenzodiazepinesBenzazepinesHeterocyclic Compounds, 2-Ring

Study Officials

Aung Naing, MD
M.D. Anderson Cancer Center
PRINCIPAL INVESTIGATOR

Enrollment

57 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 1
Allocation: NA
Masking: NONE
Purpose: TREATMENT
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

June 20, 2007

First Posted

June 21, 2007

Study Start

October 2006

Date type not reported

This date has not been verified as actual or estimated.

Olanzapine in Patients With Advanced Cancer and Weight Loss

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

Olanzapine

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Related Links

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

Olanzapine

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Related Links

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations